

Corporate Fact Sheet

Company Overview

Bilcare Research (BSE: BIL, CODE: 526853) is a unique organization with a strong research foundation and an unending quest for global leadership. Bilcare offers customer-centric innovation for pharmaceutical packaging, card solutions, specialty film solutions and clinical trial supplies management. Through nonClonableID™ technology, Bilcare offers path breaking business solutions in brand protection and business intelligence. An organization made up of motivated people, Bilcare believes in going that extra mile to spread excellence and joy.

Our Businesses

- Pharma Packaging Innovations (PPI)
- Packaging Films Solutions
- Global Clinical Supplies (GCS)
- nonClonableID Technologies
- Cards Solutions
- Specialty Films Solutions

Global Footprint

Europe

- Films production plants in Germany and Italy
- Clinical trial services facility in UK - MHRA approved site

USA

- Clinical trial services facility
- 14 acre FDA & DEA approved site
- Films & foils secondary production

India

- Films & foils production
- Clinical trial services facility – 1st in Asia
- Research facilities – DSIR approved
- Award winning – OPPI “Best Vendor” consecutively

Singapore

- Films production & research centre
- Clinical trial services facility
- Pioneer Status from Singapore Govt.

Bilcare’s Competitive Edge

- 2300 strong team working across US, Europe & Asia
- Research-driven customer-centric organization
- Comprehensive and innovative product portfolio
- Global footprint with 13 production & operations locations across Asia, Europe and the US
- State-of-the-art, award winning research and manufacturing facilities

Customers

Bilcare Research caters to over 2500 customers worldwide, including the following, among others:



RANBAXY

Strategy

Bilcare Research maintains a defined focus on meeting the challenges faced by the global pharmaceutical industry. We will continue to drive innovation in developing packaging solutions to address the stagnating sales of existing brands in the market place and bolstering the drug discovery pipeline through clinical service solutions.

Board of Directors as on September 30, 2010

- | | |
|-------------------------|----------------------|
| • Mohan Bhandari | • Dr. Arthur Carty |
| • Dr. Praful Naik | • Rajendra Tapadia |
| • Dr. Kalyani Gandhi | • Dr. Bhojraj Suresh |
| • Dr. Volker Huelck | • Dr. R V Chaudhari |
| • Chandra Prakash Jaggi | |

Financial Performance

The consolidated net sales for the quarter ended September 30, 2010, stood at Rs.465.99 crores, showing a growth of 77% over the corresponding quarter of the previous year; with the consolidated EBITDA increasing to Rs.100.43 crores from Rs.62.39 crores of the corresponding quarter of the previous year, a growth of 61%. Net profit for the quarter stood at Rs.46.53 crores as against Rs.27.85 crores in the corresponding quarter of the previous year, showing a growth of 67%.

Research & Operations	Regional Offices	Representative Offices
<p>Bilcare Singapore Pte. Ltd. 52 Changi South Street 1, Singapore 486161. direct-sg@bilcare.com</p> <p>Bilcare Limited 1028 Shirol, Rajgurunagar, Pune 410505. direct-in@bilcare.com</p> <p>Bilcare Inc 300 Kimberton Road, Phoenixville PA 19460. direct-us@bilcare.com</p> <p>Bilcare GCS (Europe) Ltd Waller House, Elvicta Business Park, Crickhowell, Powys NP8 1DF UK. direct-europe@bilcare.com</p> <p>Bilcare Research GmbH Radebeulstr. 1, 79219 Staufen, Germany. info.solutions@bilcare.com</p> <p>Bilcare Fucine S.r.l. Via dell'Artigianato, 6, 38026 Fucine di Ossana (TN), Italy.</p> <p>Bilcare Research S.r.l. Via XXIV Maggio, 1, 21043 Castiglione Olona (VA) Italy.</p> <p>Bilcare Research Inc. P.O. Box 537, 1389 School House Road, Delaware City, DE 19706-0537 USA.</p> <p>Bilcare Research GmbH Schlossmattenstr. 2, 79268 Bötzingen, Germany.</p> <p>Bilcare Research GmbH Industriestr. 9, 06369 Südl. Anhalt, OT Weißandt-Göolzau, Germany.</p> <p>Bilcare Fucine S.r.l. Via XXIV Maggio, 1, 21043 Castiglione Olona, (VA), Italy.</p>	<p>Bilcare Room 701, No.89 Xing Tai Road, Baiyu District, Guangzhou. direct-ch@bilcare.com</p> <p>Bilcare Research AG Gewerbestr. 12, 4123 Allschwil, Switzerland. info.solutions@bilcare.com</p> <p>Bilcare Marketing America Latina Ltda. Alameda Campinas 834 - Apto 111, Jardim Paulista - CEP:01404-001, Sao Paulo. direct-br@bilcare.com</p> <p>Bilcare 5-Eurong Street, Wahroonga, NSW 2076 Sydney. direct-au@bilcare.com</p>	<p>Argentina Bangladesh Chile Colombia Czech Republic Egypt France Indonesia Iran Israel Jordan Korea Malaysia Mexico Pakistan Saudi Arabia South Africa Spain Taiwan Thailand Turkey Venezuela Vietnam</p>

© 2011, Bilcare Limited. All Rights Reserved.

FORWARD LOOKING STATEMENTS: This fact sheet is neither an offer nor solicitation to buy or sell any securities mentioned and is for educational purposes only. While it is believed all sources of information are factual and reliable, in no way is it represented or guaranteed that the description or statements herein are accurate and complete. The reader should verify all claims and do his/her/their own due diligence before investing in any securities mentioned. Any forward-looking statements involve risks and uncertainties. Bilcare Research does not undertake any obligation to update any forward looking statement, except as required under applicable law. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent of Bilcare Limited. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.